MedTrace Logo

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT01248247 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2022-01-12

Study results available
· View outcomes & findings →

Summary

Different people have different biomarkers (chemical "markers" in the blood that may be related to your reaction to study drugs). If researchers know about your biomarkers before you receive treatment, they may be able to prescribe a treatment that is better suited to your body's specific needs.

The goal of this clinical research study is to learn if drug or drug combinations based on your biomarkers can help to control NSCLC. The safety of these drug combinations will also be studied.

Conditions

Interventions

DRUG

Erlotinib

150 mg by mouth each day of a 28 day cycle.

DRUG

AZD6244

100 mg by mouth daily of a 28 day cycle.

DRUG

MK-2206

100 mg by mouth every week of a 28 day cycle.

DRUG

Sorafenib

400 mg by mouth twice a day for a 28 day cycle.

DRUG

Erlotinib

150 mg by mouth daily of a 28 day cycle.

DRUG

MK-2206

135 mg by mouth every week of a 28 day cycle.

Sponsors & Collaborators

Principal Investigators

  • Marcelo V. Negrao, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-02
Primary Completion
2020-11-30
Completion
2020-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01248247 on ClinicalTrials.gov